By Jeff ReevesNEW YORK ( InvestorPlace) -- Dividend stocks remain some of the most popular investments out there for buy-and-hold investors. And few income-oriented icons are more closely watched than Warren Buffett. At least, Buffett and Berkshire Hathaway ( BRK.B - Get Report) used to seem like they were big on dividends . . . The most notable changes in Berkshire's August filing included the end of a big dividend payer -- Intel ( INTC) dropped off Buffett's holdings altogether -- and some interesting new plays and increased positions, with many of those investments not paying a penny in distributions. Seems like portfolio managers Todd Combs and Ted Weschler are moving away from traditional Bershire stocks. But Buffett & Co. haven't given up on dividends altogether. There are a number of big payers -- yielding more than 3% -- worth noting. The biggest sector for dividends in the Buffett portfolio is health care, and the biggest single stock is U.K. drugmaker GlaxoSmithKline ( GSK - Get Report). GSK made a splash recently with the buyout of Human Genome Sciences for $3.6 billion. That could yield benefits in the long term with an addition to the product pipeline and the potential for blockbusters to replace older medications. Of course, share prices have lagged year-to-date because that much-anticipated blockbuster hasn't shown up yet. But there's the big yield to consider in GSK while you wait. However, note that GSK isn't as consistent as domestic pharmaceuticals when it comes to distributions -- the past four quarterly payouts range between 52 cents and 82 cents a share. But add up the past four consecutive payments, and you get about $2.43 annually for a hefty 5.2% yield. Health care is a hugely important sector in the Berkshire portfolio. There has been a lot of drug news lately that is inspiring for Big Pharma. Eli Lilly ( LLY - Get Report) recently received a favorable report on a possible Alzheimer's cure, and Merck ( MRK - Get Report) proved its drug pipeline is paying off with a surge after strong results for its osteoporosis medication. This proves the old guard can and will survive even amid patent expirations. What other Berkshire Hathaway dividend stocks in health care (and elsewhere) are noteworthy? Visit the InvestorPlace website to check out the nine other holdings that make up the 10 best Buffett dividend stocks. Jeff Reeves is the editor of InvestorPlace.com and the author of "The Frugal Investor's Guide to Finding Great Stocks." Write him at firstname.lastname@example.org or follow him on Twitter via @JeffReevesIP. This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
More from Opinion
Morgan Stanley Looks Like a Buy Following Impressive Q3 Execution
In the third quarter, Morgan Stanley provided evidence that it can deliver strong results, even when the macroeconomic landscape seems far from ideal.
Goldman Sachs: Should You Bet on Its Business Transformation?
Goldman Sachs is a higher-risk, higher-reward play that bargain hunters looking for a potentially successful business model transition story might want to consider.
PepsiCo: The Unlikely Growth Story Continues to Roll
Given the combination of solid execution, strong fundamentals and the diversification benefits of the stock, PepsiCo looks like a compelling buy following the company's strong third quarter earnings report.
There Will Be No Economic Collapse From a No-Deal Brexit
The EU can have Brexit and keep zero tariffs, which ought to be obvious.
Citigroup: Tread Carefully Around Bank Stocks Ahead of Earnings Season
Citigroup will probably have the robustness of global consumer activity to help it support financial results in the third quarter. But the current interest rate environment and a soft institutional services business pose significant challenges for the New York City-based mega bank.